SmgGDS expression is increased in breast, lung, and prostate cancer (Tew et al., 2008; Zhi et al., 2009; Hauser et al., 2014), and elevated SmgGDS expression is associated with poor prognosis in breast cancer (Hauser et al., 2014). Here, RAP1GDS1 is linked to prostate carcinoma.